<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951210</url>
  </required_header>
  <id_info>
    <org_study_id>1202-2</org_study_id>
    <nct_id>NCT00951210</nct_id>
  </id_info>
  <brief_title>Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)</brief_title>
  <official_title>Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pluristem Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pluristem Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of PLX-PAD, Intra-muscular injections
      for the treatment of CLI patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events; Amputation incidence, Death incidence &amp; Rehospitalization incidence</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological reaction</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>PLX-PAD low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM injection Single treatment; multiple injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLX-PAD high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM injection Double treatment; multiple injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PLX-PAD</intervention_name>
    <description>IM injection</description>
    <arm_group_label>PLX-PAD low dose</arm_group_label>
    <arm_group_label>PLX-PAD high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of critical limb ischemia defined as persistent, recurring ischemic rest
             pain for at least two (2) weeks, and/or ulceration or gangrene of the foot or toe,
             with ABI &lt; 0.6 or/and TBI &lt; 0.4

          2. Rutherford category 4-5

          3. Non candidate for revascularization or endovascular intervention based on unfavorable
             vascular anatomy or significant co-morbid medical conditions as confirmed by vascular
             study (e.g., angiogram, MRA) obtained within 3 months prior screening visit and signed
             approval of vascular surgeon. The decision to classify the subject as a non-candidate
             will be made by the investigator and confirmed by an independent third party vascular
             surgeon who is not participating in the study.

          4. In the opinion of the investigator, major amputation is not anticipated over a period
             of three (3) months.

          5. Those diabetic subjects who are on optimal diabetes medication, with an HbA1c &lt; 8%

        Exclusion Criteria:

          1. Uncontrolled hypertension (defined as diastolic blood pressure &gt; 110 mmHg or systolic
             blood pressure &gt; 180 mmHg during screening).

          2. Wounds with severity greater than Grade 2 on the Wagner Scale

          3. Life-threatening ventricular arrhythmia - except if an ICD is implanted - or unstable
             angina - characterized by increasingly frequent episodes with modest exertion or at
             rest, worsening severity, and prolonged.

          4. ST segment elevation myocardial infarction and/or TIA/CVA within six (6) months prior
             to enrollment.Patients with severe congestive heart failure (i.e. NYHA Stage IV)

          5. In the opinion of the investigator, the patient is unsuitable for cellular therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>May 24, 2015</last_update_submitted>
  <last_update_submitted_qc>May 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>Critical limb ischemia</keyword>
  <keyword>PAD</keyword>
  <keyword>CLI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

